Saturday, 17 October 2026European Markets

BLEECKER Stock Is 20% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of bleecker (cac 40: blee.pa) rose by a staggering 20.42% in 10 sessions from €191 to €230.00 at 07:54 est on friday, after three sequential sessions in a row of losses. cac 40 is jumping 0.89% to €7,366.16, after four consecutive sessions in a row of gains.

about bleecker

bleecker société anonyme, a property company, operates in the real estate sector in france. the company develops and manages industrial premises, offices, and logistics platforms. as of august 31, 2010, it had 26 properties or property complexes covering a surface area of 208,228 square meters. the company is based in paris, france.

earnings per share

as for profitability, bleecker has a trailing twelve months eps of €28.31.

pe ratio

bleecker has a trailing twelve months price to earnings ratio of 8.12. meaning, the purchaser of the share is investing €8.12 for every euro of annual earnings.

volatility

bleecker's last week, last month's, and last quarter's current intraday variation average was 4.55%, 1.11%, and 4.72%.

bleecker's highest amplitude of average volatility was 4.55% (last week), 7.82% (last month), and 4.72% (last quarter).

volume

today's last reported volume for bleecker is 12 which is 69.56% below its average volume of 23.

more news about bleecker (blee.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com